1. Home
  2. PNRG vs NGNE Comparison

PNRG vs NGNE Comparison

Compare PNRG & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PNRG

PrimeEnergy Resources Corporation

HOLD

Current Price

$272.50

Market Cap

386.8M

Sector

Energy

ML Signal

HOLD

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$28.04

Market Cap

327.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PNRG
NGNE
Founded
1973
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
386.8M
327.8M
IPO Year
1995
2014

Fundamental Metrics

Financial Performance
Metric
PNRG
NGNE
Price
$272.50
$28.04
Analyst Decision
Hold
Strong Buy
Analyst Count
1
7
Target Price
$160.00
$63.57
AVG Volume (30 Days)
42.4K
130.0K
Earning Date
04-16-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
0.93
EPS
10.86
N/A
Revenue
$189,052,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$18.18
N/A
P/E Ratio
$24.34
N/A
Revenue Growth
N/A
N/A
52 Week Low
$126.40
$14.65
52 Week High
$265.72
$37.27

Technical Indicators

Market Signals
Indicator
PNRG
NGNE
Relative Strength Index (RSI) 71.14 51.76
Support Level $162.70 $18.25
Resistance Level N/A $29.05
Average True Range (ATR) 13.41 2.42
MACD 4.16 -0.24
Stochastic Oscillator 90.31 37.54

Price Performance

Historical Comparison
PNRG
NGNE

About PNRG PrimeEnergy Resources Corporation

PrimeEnergy Resources Corp is an independent oil and natural gas company that is engaged in acquiring, developing, and producing oil and natural gas. It owns producing and non-producing properties located in Texas and Oklahoma. The company's business activities include development and exploratory drilling and providing well servicing support operations for many of the onshore oil and gas wells through its subsidiaries. It is also active in the acquisition of producing oil and gas properties through joint ventures with industry partners.

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Share on Social Networks: